vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and NorthEast Community Bancorp, Inc. (NECB). Click either name above to swap in a different company.

NorthEast Community Bancorp, Inc. is the larger business by last-quarter revenue ($26.4M vs $19.6M, roughly 1.4× STANDARD BIOTOOLS INC.). NorthEast Community Bancorp, Inc. runs the higher net margin — 40.9% vs -177.4%, a 218.3% gap on every dollar of revenue. On growth, NorthEast Community Bancorp, Inc. posted the faster year-over-year revenue change (3.9% vs -11.5%). NorthEast Community Bancorp, Inc. produced more free cash flow last quarter ($50.8M vs $-23.1M). Over the past eight quarters, NorthEast Community Bancorp, Inc.'s revenue compounded faster (1.8% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

NorthEast Community Bancorp, Inc. (MD) is a U.S.-based bank holding company operating primarily in the Mid-Atlantic region. It provides a comprehensive suite of consumer and commercial banking services, including deposit products, mortgage loans, small business financing, and wealth management solutions to individual and local enterprise clients.

LAB vs NECB — Head-to-Head

Bigger by revenue
NECB
NECB
1.4× larger
NECB
$26.4M
$19.6M
LAB
Growing faster (revenue YoY)
NECB
NECB
+15.4% gap
NECB
3.9%
-11.5%
LAB
Higher net margin
NECB
NECB
218.3% more per $
NECB
40.9%
-177.4%
LAB
More free cash flow
NECB
NECB
$73.9M more FCF
NECB
$50.8M
$-23.1M
LAB
Faster 2-yr revenue CAGR
NECB
NECB
Annualised
NECB
1.8%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
NECB
NECB
Revenue
$19.6M
$26.4M
Net Profit
$-34.7M
$10.8M
Gross Margin
48.5%
Operating Margin
-168.5%
59.0%
Net Margin
-177.4%
40.9%
Revenue YoY
-11.5%
3.9%
Net Profit YoY
-28.8%
5.8%
EPS (diluted)
$-0.09
$0.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
NECB
NECB
Q4 25
$26.4M
Q3 25
$19.6M
$27.0M
Q2 25
$21.8M
$25.9M
Q1 25
$40.8M
$25.5M
Q4 24
$25.4M
Q3 24
$22.1M
$27.6M
Q2 24
$22.5M
$27.0M
Q1 24
$45.5M
$25.5M
Net Profit
LAB
LAB
NECB
NECB
Q4 25
$10.8M
Q3 25
$-34.7M
$11.9M
Q2 25
$-33.5M
$11.2M
Q1 25
$-26.0M
$10.6M
Q4 24
$10.2M
Q3 24
$-26.9M
$12.7M
Q2 24
$-45.7M
$12.8M
Q1 24
$-32.2M
$11.4M
Gross Margin
LAB
LAB
NECB
NECB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
NECB
NECB
Q4 25
59.0%
Q3 25
-168.5%
61.6%
Q2 25
-118.1%
59.5%
Q1 25
-80.8%
57.4%
Q4 24
57.0%
Q3 24
-120.9%
63.6%
Q2 24
-134.5%
65.6%
Q1 24
-132.2%
62.7%
Net Margin
LAB
LAB
NECB
NECB
Q4 25
40.9%
Q3 25
-177.4%
44.0%
Q2 25
-153.7%
43.1%
Q1 25
-63.8%
41.4%
Q4 24
40.1%
Q3 24
-122.0%
45.9%
Q2 24
-203.3%
47.5%
Q1 24
-70.6%
44.5%
EPS (diluted)
LAB
LAB
NECB
NECB
Q4 25
$0.78
Q3 25
$-0.09
$0.87
Q2 25
$-0.09
$0.82
Q1 25
$-0.07
$0.78
Q4 24
$0.74
Q3 24
$-0.07
$0.95
Q2 24
$-0.12
$0.97
Q1 24
$-0.27
$0.86

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
NECB
NECB
Cash + ST InvestmentsLiquidity on hand
$129.4M
$81.2M
Total DebtLower is stronger
$70.0M
Stockholders' EquityBook value
$399.7M
$351.7M
Total Assets
$539.6M
$2.1B
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
NECB
NECB
Q4 25
$81.2M
Q3 25
$129.4M
$64.3M
Q2 25
$158.6M
$59.4M
Q1 25
$150.9M
$89.5M
Q4 24
$78.3M
Q3 24
$210.6M
$97.8M
Q2 24
$269.8M
$113.9M
Q1 24
$287.1M
$107.4M
Total Debt
LAB
LAB
NECB
NECB
Q4 25
$70.0M
Q3 25
$170.0M
Q2 25
$135.0M
Q1 25
Q4 24
Q3 24
$55.2M
$7.0M
Q2 24
$55.1M
$47.0M
Q1 24
$55.0M
$47.0M
Stockholders' Equity
LAB
LAB
NECB
NECB
Q4 25
$351.7M
Q3 25
$399.7M
$344.0M
Q2 25
$424.5M
$336.7M
Q1 25
$454.6M
$327.2M
Q4 24
$318.3M
Q3 24
$489.3M
$309.6M
Q2 24
$510.3M
$300.0M
Q1 24
$577.3M
$288.9M
Total Assets
LAB
LAB
NECB
NECB
Q4 25
$2.1B
Q3 25
$539.6M
$2.1B
Q2 25
$557.0M
$2.0B
Q1 25
$579.6M
$1.9B
Q4 24
$2.0B
Q3 24
$681.5M
$2.0B
Q2 24
$708.7M
$1.9B
Q1 24
$777.7M
$1.9B
Debt / Equity
LAB
LAB
NECB
NECB
Q4 25
0.20×
Q3 25
0.49×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
0.11×
0.02×
Q2 24
0.11×
0.16×
Q1 24
0.10×
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
NECB
NECB
Operating Cash FlowLast quarter
$-22.2M
$52.6M
Free Cash FlowOCF − Capex
$-23.1M
$50.8M
FCF MarginFCF / Revenue
-118.1%
192.3%
Capex IntensityCapex / Revenue
4.5%
6.6%
Cash ConversionOCF / Net Profit
4.86×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$89.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
NECB
NECB
Q4 25
$52.6M
Q3 25
$-22.2M
$14.1M
Q2 25
$-20.7M
$15.6M
Q1 25
$-30.3M
$10.9M
Q4 24
$48.7M
Q3 24
$-27.9M
$14.4M
Q2 24
$-39.0M
$11.1M
Q1 24
$-62.5M
$12.9M
Free Cash Flow
LAB
LAB
NECB
NECB
Q4 25
$50.8M
Q3 25
$-23.1M
$13.6M
Q2 25
$-22.6M
$14.9M
Q1 25
$-35.3M
$10.6M
Q4 24
$48.2M
Q3 24
$-30.1M
$14.2M
Q2 24
$-41.0M
$11.0M
Q1 24
$-63.3M
$12.8M
FCF Margin
LAB
LAB
NECB
NECB
Q4 25
192.3%
Q3 25
-118.1%
50.5%
Q2 25
-103.6%
57.3%
Q1 25
-86.6%
41.4%
Q4 24
189.3%
Q3 24
-136.4%
51.5%
Q2 24
-182.2%
40.8%
Q1 24
-138.9%
50.3%
Capex Intensity
LAB
LAB
NECB
NECB
Q4 25
6.6%
Q3 25
4.5%
1.6%
Q2 25
8.7%
2.9%
Q1 25
12.4%
1.5%
Q4 24
2.0%
Q3 24
10.2%
0.6%
Q2 24
8.6%
0.5%
Q1 24
1.7%
0.3%
Cash Conversion
LAB
LAB
NECB
NECB
Q4 25
4.86×
Q3 25
1.18×
Q2 25
1.40×
Q1 25
1.04×
Q4 24
4.77×
Q3 24
1.14×
Q2 24
0.87×
Q1 24
1.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

NECB
NECB

Segment breakdown not available.

Related Comparisons